Synapse - Gynecologic Medicine Service

Results (2180)

Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study

Meeting Abstract

Matulonis, U. A.; Oaknin, A.; Pignata, S.; denys, H.; Colombo, N.; Van Gorp, T.; Konner, J. A.; Romeo, M.; Harter, P.; Murphy, C. G.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Cell-free DNA analysis as a molecular tool to monitor response to immune checkpoint inhibition in endometrial cancer

Meeting Abstract

Manning-Geist, B.; Patel, J. A. A.; Marra, A.; Da Cruz Paula, A.; Hanlon, E. J.; Abu-Rustum, N.; Shah, R. H.; Berger, M. F.; Hensley, M. L.; Zamarin, D.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775

Meeting Abstract

Makker, V.; Colombo, N.; Santin, A.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Ray-Coquard, I. L.; Kim, Y. M.; Guerra, E. M.; Huang, J.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification

Meeting Abstract

Makker, V.; Perez-Fidalgo, J. A.; Bergamini, A.; Spitz, D. L.; Van Gorp, T.; Sehouli, J.; Klat, J.; Perri, T.; Oza, A. M.; Hogdall, E. V. S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205

Meeting Abstract

Lorusso, D.; Vergote, I.; O'Cearbhaill, R. E.; Westermann, A. M.; Banerjee, S. N.; Van Nieuwenhuysen, E.; Iglesias, D. A.; Collins, D. C.; Cibula, D.; Madsen, K.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer

Meeting Abstract

Lukashchuk, N.; Armenia, J.; Tobalina, L.; Carr, T. H.; Milenkova, T.; Liu, Y. L.; Penson, R. T.; Robson, M. E.; Harrington, E.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development

Meeting Abstract

Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer

Meeting Abstract

Landen, C. N.; Buckanovich, R. J.; Sill, M.; Mannel, R. S.; Walker, J. L.; Disilvestro, P.; Mathews, C. A.; Mutch, D. G.; Hernandez, M.; Martin, L. P.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody-drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress)

Meeting Abstract

Lakhani, N. J.; Friedman, C. F.; Perez, C. A.; Wehr, A.; McGoldrick, S. M.; LoRusso, P.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)

Meeting Abstract

Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save